Trevi Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
07 avr. 2021 07h30 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates
25 mars 2021 16h05 HE
|
Trevi Therapeutics
Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021 Cash Position Expected to Fund Operations into the Second Quarter of 2022 NEW...
Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25
18 mars 2021 16h05 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., March 18, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference
18 févr. 2021 16h05 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics Appoints William Forbes, Pharm.D. as Chief Development Officer
01 févr. 2021 07h30 HE
|
Trevi Therapeutics
Industry Veteran to Lead the Clinical Development of Haduvio™ in Multiple Indications NEW HAVEN, Conn., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage...
Trevi Therapeutics Announces Third Quarter 2020 Financial Results and Business Update
11 nov. 2020 16h05 HE
|
Trevi Therapeutics
PRISM Trial of Haduvio™ for Severe Pruritus in Patients with Prurigo Nodularis Exceeds Halfway Enrollment Milestone Phase 2 Chronic Cough Trial in Patients with IPF Enrolled First New Subject...
Trevi Therapeutics to Present at Stifel Healthcare Conference
10 nov. 2020 07h30 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics to Report Q3 2020 Financial Results on November 11
04 nov. 2020 16h05 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics Announces the Hiring of Key Talent
13 oct. 2020 16h05 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics to Present at H.C. Wainwright Global Investment Conference
09 sept. 2020 16h05 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...